(0.09%) 5 522.00 points
(0.13%) 39 897 points
(0.19%) 19 789 points
(-0.06%) $81.58
(0.57%) $2.83
(-0.23%) $2 339.10
(0.17%) $29.58
(0.45%) $1 006.30
(0.06%) $0.932
(-0.02%) $10.53
(0.03%) $0.788
(-0.85%) $87.25
49.24% $ 0.0885
Live Chart Being Loaded With Signals
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform...
Stats | |
---|---|
Dzisiejszy wolumen | 46 822 |
Średni wolumen | 0 |
Kapitalizacja rynkowa | 8.44M |
EPS | $-2.47 ( Q1 | 2024-05-14 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
0 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00700 (7.91%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-22 | Mckee Kelly T. Jr. | Buy | 6 944 | Common Stock |
2023-09-25 | Mckee Kelly T. Jr. | Buy | 9 653 | Common Stock |
2023-08-25 | Dodd David A | Buy | 35 087 | Common Stock |
2023-08-18 | Reynolds Mark | Buy | 10 000 | Common Stock |
2023-08-01 | Spencer John N Jr | Buy | 50 000 | Stock Option |
INSIDER POWER |
---|
99.97 |
Last 95 transactions |
Buy: 15 412 165 | Sell: 50 000 |
Wolumen Korelacja
GeoVax Labs, Inc. Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
GeoVax Labs, Inc. Korelacja - Waluta/Towar
GeoVax Labs, Inc. Finanse
Annual | 2023 |
Przychody: | $0 |
Zysk brutto: | $-74 169.00 (0.00 %) |
EPS: | $-14.29 |
FY | 2023 |
Przychody: | $0 |
Zysk brutto: | $-74 169.00 (0.00 %) |
EPS: | $-14.29 |
FY | 2022 |
Przychody: | $81 000.00 |
Zysk brutto: | $24 716.00 (30.51 %) |
EPS: | $-12.39 |
FY | 2021 |
Przychody: | $385 501 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $0 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
GeoVax Labs, Inc.
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej